Shares of CareDx, Inc declined 4.8% post-earnings as investors reacted negatively to a more cautious outlook and slower momentum in key business drivers. Management's revised strategy update and portfolio shifts did not fully allay concerns about deceleration in core growth metrics.

• The company announced the divestiture of its Lab Products business and an acquisition of Navaris, signaling a pivot in portfolio priorities.
• Management emphasized ongoing pipeline progress, including the upcoming AlloSure liver program and the planned launch of HistoMap kidney, but specifics on adoption or revenue contribution were limited.
• Workflow integration remains a focus, with a target of 50% of testing volume through Epic-integrated sites by year-end; progress was noted, but ultimate impact remains to be demonstrated.
• Clinical adoption outside core kidney testing (notably HeartCare and lung indications) was discussed, but updates suggested incremental rather than breakout momentum.
• The updated 2026 outlook was highlighted on the call, but the market's negative reaction suggests investors remain concerned about growth trajectory and the impact of strategic repositioning.